Close Icon We use cookies to improve your website experience. To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy. By continuing to use the website, you consent to our use of cookies.

Pharma Intelligence is part of the Informa Intelligence Division of Informa PLC

This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Products:

Pharma Consulting

Close Icon

Hot topics

Thought leadership

Research and development strategy

Close Icon

Events

Conferences 2019

Awards

Upcoming Webinars

Webinar recordings

Close Icon

Global Search Configuration

Search Site Products & Services
Close Icon

Search by Keyword

Focus
Needs

Pharma intelligence for marketing agencies

Gain insight into the pharmaceutical market landscape – we’ll help you communicate complex ideas clearly and develop customer-centric propositions.

Supporting market access strategy

With the pharma and healthcare sector facing increasing challenges, your clients rely more than ever on independent intelligence. As a marketer, you have to engage with multiple audiences across a variety of channels and to communicate complex information simply and persuasively.

We give you the means to identify future innovation and new market opportunities, develop customer-centric propositions, and keep a close eye on competitors. We can also help with branding, multi-channel communication and more.

What we offer

As the trusted partner of the top 50 pharmaceutical companies and 10 contract research organizations, our pharma intelligence will help you build a complete picture of the market and get access to past, current and future trends and analysis.

How it helps

You’ll get cutting-edge insights on the size and shape of markets, competitive threats, actionable customer perceptions and industry innovations.

Our accurate, reliable intelligence will help you:

Access in-depth knowledge from drug discovery to market access
Acquire a comprehensive understanding of the global pharma market
Get in-depth coverage of the entire pharmaceutical value-chain

Our unique strengths

Understand your clients’ world

Gain comprehensive knowledge of the global pharma market with our complete coverage.

Think ahead

Respond to market events, identify opportunities and anticipate changes by tracking updates impacting the pharmaceutical industry.

Deliver tailored solutions

Use our data and insight to create solutions to suit your clients’ needs.

Benefit from a dedicated service

Our services come with dedicated client service and analyst support.

View more
View Less

Relevant products

Our popular solutions

Key benefits:

Direct access to your target Pharma audience
A cohesive marketing campaign
Effective reporting

Lead generation

Key benefits:

Direct access to your target Pharma audience
Multi or single channel campaigns
Measurable results

Our products and audiences

Key benefits:

Tailored and targeted campaigns
Multiple channels and content formats
Right message for the right audience

View all content

Generics Bulletin

Global Industry Hails Bioequivalence Progress

By Aidan Fry 11 Dec 2019

For the first time, a working group within the International Council for Harmonization has started work on a regulatory topic specifically tailored to the global generics and biosimilars industry.

View article
HBW Insight

US Senate Passes First Monograph Reform Bill After House Passed Three

By Malcolm Spicer 11 Dec 2019

Senate's Over-the-Counter Monograph Safety, Innovation, and Reform Act goes next for consideration by House, which has had a bill by the same title on its floor for a vote since it was passed by Energy and Commerce Committee in late June.

View article
HBW Insight

Fragrance Creators Association Readies New Consumer Website To Cap 'Year For The Public'

By Ryan Nelson 11 Dec 2019

Farah Ahmed, president and CEO of the Fragrance Creators Association, discusses the trade group’s expansion in recent years beyond immediate regulatory and legislative concerns to a platform for robust member collaboration in the name of positively impacting the world.

View article
Pink Sheet

Rising's Generic Price Fixing Settlement Follows Bankruptcy, Cooperation With DOJ

By Brenda Sandburg 06 Dec 2019

Rising Pharmaceuticals agrees to pay $3.1m, admits to conspiring to fix prices for hypertension drug, and enters into deferred prosecution agreement. Pfizer asks court to be removed from complaint by state AGs.

View article
HBW Insight

Future of CBD In Supplements: NDI Notification Looms As Regulatory Path

By Malcolm Spicer 06 Dec 2019

Recent statement that FDA has not found evidence supporting CBD as GRAS for use in human or animal food potentially points to NDI notifications as the only option manufacturers, marketers and other businesses will have to convince agency about safety for CBD and other hemp-derived substances used in dietary supplements.

View article
HBW Insight

GSK Launches OTC Fluticasone In Japan Following Switch

By Tom Gallen 06 Dec 2019

GSK has launched Flunase in Japan following the switch of fluticasone propionate. JSMI’s Toshi Tominaga gives his assessment of the product’s prospects as an OTC drug.

View article
Generics Bulletin

Ophthalmics Are Next Frontier For Teligent

By Aidan Fry 06 Dec 2019

US niche generics player Teligent intends to use its expertise in topical and injectable drugs manufacturing to push into the North American ophthalmics sector.

View article
Scrip

Pharma Finds Its Way in AI

By Leah Samuel 06 Dec 2019

Early adopters of artificial intelligence are discovering how best to use it. Some of them are sharing lessons they have learned.

View analysis
Scrip

More Top Level Pharma Exits In India As Cipla COO Departs

By Anju Ghangurde 06 Dec 2019

Cipla’s global chief operating officer is leaving the company to pursue new interests, amid a spate of top-level exits that have marked the pharma sector in India in 2019.

View article
Scrip

Novartis Sees Reimbursement Advantage For PCSK9 Launch

By Jessica Merrill 28 Nov 2019

Administration under the medical benefit/Medicare Part B could mean easier reimbursement. The company outlined early plans for the launch of inclisiran after announcing it will buy The Medicines Company for $9.7bn.

Topic Business Strategies Deal trends Reimbursement

View analysis
Scrip

Amid New M&A Rumors, Amarin CEO Focused On Vascepa Approval

By Andrew McConaghie 28 Nov 2019

John Thero insists company is focused on approval and launch, as interest in European rights grow.

View article
Pink Sheet

Former FDA Commissioner Frank Young Passes Away At 88

By Michael Cipriano 28 Nov 2019

From the approval of AZT to the generic drug scandal, Frank Young oversaw many seminal events at US FDA while commissioner from 1984 to 1989. After leaving the agency, he managed the approval of the NDA for Braeburn's opioid dependence drug Probuphine. Young passed away following a short bout with cancer.

View article
HBW Insight

Sunscreen Industry Faces Major Challenge In GRASE Push That OTC Monograph Reform Would Solve

By Ryan Nelson 28 Nov 2019

Industry advocates working to support GRASE determinations for eight UV filters are faced with a dilemma. They would like to share nonpublic studies with the FDA on a confidential basis – at least to get initial temperature readings from the agency as to the studies’ usefulness in addressing data gaps – but under the current OTC monograph framework, no such pathway exists.

View article
Generics Bulletin

Celltrion's Remsima SC Ready For Early 2020 Launch

By David Wallace 28 Nov 2019

Celltrion says it is ready to roll out its Remsima SC subcutaneous infliximab in Europe in the first quarter of 2020, after receiving a formal pan-European marketing authorization from the European Commission.

View article
HBW Insight

Complicated Regulatory Odyssey Steers FDA Toward Rule On CBD In Supplements

By Malcolm Spicer 27 Nov 2019

Before Congress de-scheduled hemp at end of 2018 and forced agency's hand on considering lawful use of ingredients derived from the plant in supplements and food, the floodgate for sales of the products was opened in 2013 by a DoJ policy change to de-emphasize enforcement of most federal marijuana laws.

View article